Paper Details

  1. Home
  2. Paper Details

A Systematic Review on Second Treatment-Free Remission (TFR) Attempt in Chronic Myeloid Leukemia (CML): Can it be Applied in Clinical Practice?

Author: AkınMehmet G, EratZeynep, EşkazanA Emre, ÇiftçilerRafiye

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This systematic review examines the use of treatment-free remission (TFR) in patients with chronic myeloid leukemia (CML). While imatinib has significantly improved outcomes for CML, TFR allows for a drug-free period after achieving remission.
Paper Details　
Original Abstract of the Article :
The prognosis and life expectancy of chronic myeloid leukemia (CML) patients have improved significantly with the launch of first tyrosine kinase inhibitor (TKI), imatinib. Maintaining at least one major molecular response in CML patients without the use of TKI is known as treatment-free remission (...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.clml.2022.09.004

データ提供：米国国立医学図書館（NLM）

Second Chances for Treatment-Free Remission in Chronic Myeloid Leukemia

The treatment landscape for chronic myeloid leukemia (CML) has undergone a remarkable transformation with the advent of tyrosine kinase inhibitors (TKIs). These powerful medications have significantly improved the prognosis and life expectancy of patients, allowing many to achieve treatment-free remission (TFR), a state where they can live without TKIs while maintaining disease control. While the first attempt at TFR (TFR1) has shown promise, some patients unfortunately experience relapse. This study delves into the intriguing possibility of a second attempt at TFR (TFR2) for those who have previously experienced relapse.

Navigating the Sands of Relapse in CML

This comprehensive review of five studies revealed that a prior unsuccessful TFR1 does not necessarily preclude the possibility of achieving TFR2. The authors found that TKIs can be safely and successfully discontinued for a second time in patients with chronic phase CML, even after experiencing relapse. The key factors influencing the success of TFR2 are the speed of molecular relapse and the duration of TKI-free time after the first attempt. These findings provide valuable insights for clinicians in managing CML and offer hope for patients who have faced relapse.

A New Era of Hope for CML Patients

The emergence of TFR strategies represents a significant advancement in the management of CML, transforming it from a life-threatening condition to a manageable chronic illness. This shift empowers patients to live fuller lives with reduced side effects and financial burden. While further research is needed to refine the understanding of TFR2 and its predictive factors, the potential for a second chance at treatment-free remission offers a ray of hope for patients navigating the challenges of CML.

Dr.Camel's Conclusion

This study is a beacon of hope for those battling CML. The journey through treatment and remission can be akin to traversing a vast desert, but the prospect of a second chance at TFR2 offers a welcome oasis, providing renewed hope and the opportunity to live a more fulfilling life.

Date :
  1. Date Completed 2022-12-20
  2. Date Revised 2023-02-14
Further Info :

Pubmed ID

36344420

DOI: Digital Object Identifier

10.1016/j.clml.2022.09.004

Related Literature

Article Analysis
・Effective treatment of chronic myeloid leukemia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.